Benefits
Glycemic control in adults and children with diabetes; insulin preparations are not interchangeable by name alone.
Named U.S. presentation only; selected label sections.
Peptide library
Insulin
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The named U.S. product label is the appropriate source for its approved use, contraindications and handling. HUMALOG insulin lispro: the label reports about one hour after SC administration. IV studies in healthy subjects reported 51–55 minutes at the studied doses. This is not the duration of glucose lowering or a safe repeat-dose interval. U-100 and U-200 device/route restrictions remain product-specific. A label extraction is not an independent appraisal of every supporting trial or approval of other products with the same ingredient.
About this assessment
Named U.S. product label sections assessed.
Product-specific editorial extraction. Complete clinical review and clinician sign-off remain pending; other jurisdictions are not inferred.
Editorial assessment · 2026-09-07
Who was studied
The population specified by this product label; other indications and jurisdictions remain outside this check.
What the sources found
Glycemic control in adults and children with diabetes; insulin preparations are not interchangeable by name alone.
Regulatory scope
U.S. label record for BLA020563. This does not confer authorization on other products using the ingredient name.
What remains unknown
Named-product label sections were expanded for pharmacokinetics, contraindications and selected handling or interaction details on September 7, 2026. This is not a complete trial-program appraisal or clinician sign-off. Other formulations, patient-specific decisions and other jurisdictions require separate assessment.
How it works
HUMALOG insulin lispro; selected vial and pen instructions
Consult the product label for pharmacology. A mechanism does not extend its approved indications.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Reported adverse effects
- Hypoglycemia can be life-threatening; changes of strength, device or regimen require close supervision.
Named U.S. presentation only; selected label sections.
Contraindications
- HUMALOG: an episode of hypoglycemia, or hypersensitivity to insulin lispro or product excipients. Never infer safety from the absence of another contraindication in this summary.
Approved product exists
Approval applies to a particular product and indication. It does not extend to every use, route, compounded preparation or research vial sold under the same compound name. Check the current prescribing information.
Sources used for this snapshot
Claim-by-claim evidence
Adverseeffects
Hypoglycemia can be life-threatening; changes of strength, device or regimen require close supervision.
Named U.S. presentation only; selected label sections.
Storage
HUMALOG unopened vials: 2–8°C. Opened vials: refrigerate or keep ≤30°C for up to 28 days. In-use pens: ≤30°C, discard after 28 days. Do not freeze; pump instructions differ.
Named U.S. presentation only; selected label sections.
Pharmacokinetics
HUMALOG insulin lispro: the label reports about one hour after SC administration. IV studies in healthy subjects reported 51–55 minutes at the studied doses. This is not the duration of glucose lowering or a safe repeat-dose interval. U-100 and U-200 device/route restrictions remain product-specific.
Named U.S. product only; label revision 20250401. Educational extraction, not complete clinical review.
Contraindications
HUMALOG: an episode of hypoglycemia, or hypersensitivity to insulin lispro or product excipients. Never infer safety from the absence of another contraindication in this summary.
Named U.S. product only; label revision 20250401. Educational extraction, not complete clinical review.
References
HUMALOG insulin lispro; selected vial and pen instructions. U.S. structured product label, effective 20250401. Selected sections only.
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.